Physician profile
Jason Hammond
NPI 1033271697
$45,156.88
in general payments reported to CMS, 2019-2025
11 companies · $56.20 in 2025
The $56.20 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,259 · 2021: $26K · 2022: $152 · 2023: $45.94 · 2024: $119 · 2025: $56.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $39,154.82 | 2019-2021 | |
| Supreme Orthopedic Systems, LLC | $5,383.54 | 2019-2023 | |
| Zimmer Biomet Holdings, INC. | $285.78 | 2021-2022 | |
| Smith+Nephew, INC. | $117.77 | 2022-2025 | |
| Stryker Corporation | $84.96 | 2019-2020 | |
| Bioventus LLC | $66.84 | 2024-2025 | Durolane |
| Medline Industries LP | $21.51 | 2024 | |
| Avanos Medical | $16.01 | 2019 | |
| Heraeus Medical, LLC. | $14.56 | 2021 | |
| Dynasplint Systems INC. | $11.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$222,428.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hammond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.